Paris, France — 30 October 2024 — Genèse Labs has launched the Exoluma™ Plant & Human series — a dual-vial system combining purified exosomes with regenerative ingredients — together with completion of CPNP registration, closing a year in which the company brought four product families to market.

Exosomes are microvesicles produced naturally by cells, acting as messengers that carry key bioactive molecules — proteins, lipids and genetic material — between cells. In recognition of their role in intercellular communication, the 2013 Nobel Prize in Physiology or Medicine was awarded for the discovery of vesicle trafficking; the 2024 Nobel Prize advanced the field a step further, recognising the role of microRNA in cell signalling and tissue regeneration. In skin treatment, exosomes are valued for regenerative properties that repair damaged cells, stimulate collagen production and ease inflammation — translating into improved firmness and texture and a more revitalised appearance.

Wound healing, anti-ageing, pigmentation improvement and hair-loss prevention are core demands in medical aesthetics. Conventional antioxidants, hyaluronic acid, botulinum toxin and stem-cell therapies each offer benefits but come with limitations in dose control, foreign-body sensation and irregular contour formation. Exosomes — nanoscale vesicles rich in miRNA and active factors — regulate the key signalling pathways governing wound healing, anti-ageing and inflammation reduction, promoting the expression of type I and type III collagen essential to skin regeneration. Their low immunogenicity, biocompatibility and ability to target specific tissues make them a promising alternative.

Exoluma™ comprises two formulations, allowing selection according to regulatory environment and treatment objective. The Human-Based (ADSC) formulation contains high-potency exosomes extracted from human adipose-derived stem cells, composed of the same lipid bilayer as human cells for high penetration into the epidermis and dermis, and stimulating collagen synthesis via the PI3K/Akt signalling pathway. The Plant-Based (Ginseng & Centella) formulation delivers broad skin activation through high particle concentration, with the natural anti-inflammatory properties of ginseng and the restorative capacity of centella making it particularly suitable for environmentally stressed or sensitive skin. Both formulations additionally incorporate probiotic-derived Lactobacillus exosomes to strengthen barrier defence and amplify the regenerative effect.

Vial 1 preserves a pure exosome concentrate in lyophilised form together with PDRN, peptides and NAD⁺, maintaining molecular stability and bioactivity. Vial 2 is an active solution responsible for hydration, nourishment, protection and recovery, incorporating hyaluronic acid and salmon hyaluronate, niacinamide, hydrolysed collagen, a peptide complex, amino acids, plant extracts, tranexamic acid, and ascorbic acid with glutathione. [Molecular composition ratios and patent numbers are reserved for professional catalogue materials.

The efficacy of Exoluma™ has been supported in skin regeneration and firmness, barrier reinforcement and hydration, skin restoration confirmed in 3D human-tissue model testing, fibroblast proliferation, and hair-growth support with reduction of hair loss. It is applicable to dry skin, atrophic scarring, sagging skin, stretch marks, damaged and ageing skin, and acne scarring, as well as thinning hair and damaged scalp.

With CPNP registration, the Exoluma™ series has established compliant status within the European framework and become distributable across every EU member state. Given the international regulatory complexity surrounding exosome products, completing European notification provides both the legal basis for EU sales and a documented record supporting subsequent registrations in other regions. The platform expanded the following year with the launch of Exoluma Exo-PDRN and the Exo-Mask sheet line.

Genèse Labs proudly announces the global launch of Exoluma™, an advanced exosome-based rejuvenation line created to redefine the landscape of regenerative aesthetics. Representing one of the company’s most significant scientific achievements to date, Exoluma™ introduces two distinct exosome technologies, allowing practitioners to select the approach best suited to their clinical philosophy and patient needs.

With Exoluma™, Genèse Labs brings forward a two-pathway rejuvenation concept designed to elevate skin regeneration at the cellular level: Exoluma™ Human Exosomes, engineered for deep regenerative performance and supporting cellular communication, renewal, and overall tissue vitality; and Exoluma™ Plant Exosomes, derived from purified botanical vesicles and offering a gentler, globally adaptable rejuvenation option ideal for sensitive-skin patients and regions with stricter regulatory frameworks. This dual-technology launch positions Exoluma™ as a versatile and globally scalable solution, reflecting the growing international demand for biologically active, high-performance skin revitalization.

To strengthen the rejuvenating performance of its exosomes, Exoluma™ incorporates a sophisticated blend of premium actives that work in synergy with cellular messengers. It includes PDRN for regeneration and improved tissue quality, peptides to support elasticity and collagen activity, niacinamide for radiance and a more uniform complexion, and hydrolyzed collagen and DNA for improved smoothness and hydration. This multi-layered combination enhances overall skin quality, promoting a bright, revitalized, and balanced appearance.

Exoluma™ addresses the increasing global demand for treatments that provide refined, natural results without excessive volumizing. Patients experience restored luminosity, renewed vitality, and smoother texture, with improvements that evolve gradually as regenerative pathways deepen. The availability of both human and plant exosome versions allows clinics to tailor treatment options—supporting everything from intensive regeneration programs to gentle rejuvenation protocols and post-procedure skin wellness.

The launch of Exoluma™ marks a pivotal milestone in Genèse Labs’ development, expanding its scientific expertise from fillers and collagen stimulators into advanced exosome biotechnology. Following the international success of RG60®, Proluma™, and Citrus Bottle, Exoluma™ strengthens the company’s position as an innovative, science-driven partner for clinics around the world. This new category reflects Genèse Labs’ long-term vision: to deliver elegant, effective, and biologically advanced aesthetic solutions that raise the standard of modern regenerative treatments.

Genèse Labs is a Paris-founded aesthetic company dedicated to science-based, regulatory-led product development across the fast-growing fields of body contouring, collagen biostimulation, and regenerative skincare. Since its foundation in 2019, the company has built its portfolio — including RG60®, Proluma™, Citrus Bottle™ and the Exoluma™ series — on three principles: scientifically verifiable formulations, regulatory compliance in every market entered, and continuous engagement with the international clinical and academic community. Genèse Labs partners with dermatologists, aesthetic physicians, and distributors worldwide to advance the standard of modern aesthetic medicine. For more information: www.geneselabs.net.